Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Deciphera Pharmaceuticals Inc (DCPH)

Deciphera Pharmaceuticals Inc (DCPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,987,853
  • Shares Outstanding, K 54,226
  • Annual Sales, $ 0 K
  • Annual Income, $ -99,850 K
  • 60-Month Beta 2.04
  • Price/Sales 86.96
  • Price/Cash Flow N/A
  • Price/Book 4.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -1.17
  • Number of Estimates 6
  • High Estimate -0.94
  • Low Estimate -1.40
  • Prior Year -0.86
  • Growth Rate Est. (year over year) -36.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
53.39 +3.20%
on 02/14/20
71.11 -22.51%
on 02/11/20
-11.47 (-17.23%)
since 01/21/20
3-Month
45.86 +20.15%
on 12/02/19
71.11 -22.51%
on 02/11/20
+6.95 (+14.43%)
since 11/21/19
52-Week
19.88 +177.16%
on 08/12/19
71.11 -22.51%
on 02/11/20
+28.64 (+108.24%)
since 02/21/19

Most Recent Stories

More News
Deciphera Pharmaceuticals, Inc. to Present at the 9th Annual SVB Leerink Global Healthcare Conference

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Steve Hoerter, President and...

DCPH : 55.10 (-1.27%)
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock

Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the closing of its previously announced...

JPM : 135.81 (-1.22%)
DCPH : 55.10 (-1.27%)
Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the pricing of its previously announced...

JPM : 135.81 (-1.22%)
DCPH : 55.10 (-1.27%)
Deciphera's NDA for GIST Drug Gets Priority Review From FDA

The FDA accepts Deciphera's (DCPH) NDA for ripretinib and grants a priority review to the same for the treatment of advanced gastrointestinal stromal tumors.

PFE : 35.72 (-0.36%)
BAYRY : 20.0699 (-0.79%)
BPMC : 67.63 (-0.50%)
DCPH : 55.10 (-1.27%)
Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the commencement of a registered...

JPM : 135.81 (-1.22%)
DCPH : 55.10 (-1.27%)
Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance of New Drug Application and Priority Review for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its New Drug Application (NDA) seeking approval for ripretinib,...

DCPH : 55.10 (-1.27%)
Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2020 Milestones

--- Commercial Preparations Underway to Support Potential Approval and Launch of Ripretinib in the U.S. for Patients with Advanced GIST -

DCPH : 55.10 (-1.27%)
Deciphera Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that Steve Hoerter, President and Chief Executive...

JPM : 135.81 (-1.22%)
DCPH : 55.10 (-1.27%)
Deciphera Pharmaceuticals Announces Submission of New Drug Application to U.S. FDA for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors

--- Positive Results from Company's INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors (GIST) Form Basis of Submission -

DCPH : 55.10 (-1.27%)
Deciphera Pharmaceuticals Announces Appointment of Ron Squarer to its Board of Directors

Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that it has appointed Ron Squarer to its Board...

ARRY : 47.85 (unch)
DCPH : 55.10 (-1.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade DCPH with:

Business Summary

Deciphera Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib which are in clinical stage. Deciphera Pharmaceuticals, LLC is based in WALTHAM, United States.

See More

Key Turning Points

2nd Resistance Point 57.06
1st Resistance Point 56.08
Last Price 55.10
1st Support Level 54.50
2nd Support Level 53.90

See More

52-Week High 71.11
Last Price 55.10
Fibonacci 61.8% 51.54
Fibonacci 50% 45.49
Fibonacci 38.2% 39.45
52-Week Low 19.88

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar